Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00828932 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

A Phase 1 study, sponsored by Eisai.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target

NCT00828932 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00828932, a Phase 1 study, has completed, sponsored by Eisai.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate and establish whether lorcaserin dose adjustment is required in patients with mild or moderate hepatic impairment.

Interventions

  • DRUG Lorcaserin

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2008-08
Est. Completion 2008-12
Phase Phase 1

Sponsor

Eisai

287 total trials

What the Registry Record Tells You About NCT00828932

The ClinicalTrials.gov registry entry for NCT00828932 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Lorcaserin is the first listed.

NCT00828932 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00828932 about?

NCT00828932 is a clinical study titled "Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment". The purpose of this study is to evaluate and establish whether lorcaserin dose adjustment is required in patients with mild or moderate hepatic impairment.

What is the current status of trial NCT00828932?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2008-08. Estimated completion is 2008-12.

What interventions are being tested in trial NCT00828932?

The interventions under investigation include: Lorcaserin (DRUG).

Who is sponsoring clinical trial NCT00828932?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.